GSE137833
Androgen Receptor Degraders Overcome Common Resistance Mechanisms Developed During Prostate Cancer Treatment
RNA-sequencing of VCaP and LNCaP, LNCaP-EnzR, or LNCaP AR-V7 overexpressing prostate cancer cell lines treated with AR degrader ARD-61. Overall design: VCaP cells treated with 100nM ARD-61 or DMSO control for 6 hours, and LNCaP, LNCaP-EnzR, or LNCaP AR-V7 cells treated with 100nM ARD-61b for 24 hours